Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 51

1.

Teneligliptin real-world efficacy assessment of type 2 diabetes mellitus patients in India (TREAT-INDIA study).

Ghosh S, Trivedi S, Sanyal D, Modi KD, Kharb S.

Diabetes Metab Syndr Obes. 2016 Nov 8;9:347-353.

2.

Efficacy and safety of teneligliptin in addition to insulin therapy in type 2 diabetes mellitus patients on hemodialysis evaluated by continuous glucose monitoring.

Yajima T, Yajima K, Hayashi M, Takahashi H, Yasuda K.

Diabetes Res Clin Pract. 2016 Dec;122:78-83. doi: 10.1016/j.diabres.2016.10.016.

PMID:
27810689
3.
4.

Teneligliptin in management of type 2 diabetes mellitus.

Sharma SK, Panneerselvam A, Singh KP, Parmar G, Gadge P, Swami OC.

Diabetes Metab Syndr Obes. 2016 Aug 16;9:251-60. doi: 10.2147/DMSO.S106133. Review.

5.

The dipeptidyl peptidase-4 (DPP-4) inhibitor teneligliptin functions as antioxidant on human endothelial cells exposed to chronic hyperglycemia and metabolic high-glucose memory.

Pujadas G, De Nigris V, Prattichizzo F, La Sala L, Testa R, Ceriello A.

Endocrine. 2016 Aug 16. [Epub ahead of print]

PMID:
27530507
6.

Teneligliptin, a Chemotype Prolyl-Thiazolidine-Based Novel Dipeptidyl Peptidase-4 Inhibitor with Insulin Sensitizing Properties.

Kutoh E, Wada A, Terayama S.

Clin Drug Investig. 2016 Oct;36(10):809-18. doi: 10.1007/s40261-016-0427-6.

PMID:
27352309
7.

Impact of teneligliptin on oxidative stress and endothelial function in type 2 diabetes patients with chronic kidney disease: a case-control study.

Sagara M, Suzuki K, Aoki C, Tanaka S, Taguchi I, Inoue T, Aso Y.

Cardiovasc Diabetol. 2016 May 17;15:76. doi: 10.1186/s12933-016-0396-3.

8.

The efficacy and safety of teneligliptin added to ongoing metformin monotherapy in patients with type 2 diabetes: a randomized study with open label extension.

Bryson A, Jennings PE, Deak L, Paveliu FS, Lawson M.

Expert Opin Pharmacother. 2016 Jul;17(10):1309-16. doi: 10.1080/14656566.2016.1190334.

PMID:
27181910
9.

Effects of teneligliptin on PDMPs and PAI-1 in patients with diabetes on hemodialysis.

Okuda Y, Omoto S, Taniura T, Shouzu A, Nomura S.

Int J Gen Med. 2016 Apr 12;9:65-71. doi: 10.2147/IJGM.S102070.

10.

Erratum to: Teneligliptin improves left ventricular diastolic function and endothelial function in patients with diabetes.

Hashikata T, Yamaoka-Tojo M, Kakizaki R, Nemoto T, Fujiyoshi K, Namba S, Kitasato L, Hashimoto T, Kameda R, Maekawa E, Shimohama T, Tojo T, Ako J.

Heart Vessels. 2016 Aug;31(8):1311-1312. No abstract available.

PMID:
26892529
11.

A novel DPP-4 inhibitor teneligliptin scavenges hydroxyl radicals: In vitro study evaluated by electron spin resonance spectroscopy and in vivo study using DPP-4 deficient rats.

Kimura S, Inoguchi T, Yamasaki T, Yamato M, Ide M, Sonoda N, Yamada K, Takayanagi R.

Metabolism. 2016 Mar;65(3):138-45. doi: 10.1016/j.metabol.2015.10.030.

PMID:
26892525
12.

Tissue distribution of teneligliptin in rats and comparisons with data reported for other dipeptidyl peptidase-4 inhibitors.

Nakamaru Y, Akahoshi F, Iijima H, Hisanaga N, Kume T.

Biopharm Drug Dispos. 2016 Jan 8. doi: 10.1002/bdd.2003. [Epub ahead of print]

13.

Efficacy and safety of teneligliptin, a novel dipeptidyl peptidase-4 inhibitor, in Korean patients with type 2 diabetes mellitus: a 24-week multicentre, randomized, double-blind, placebo-controlled phase III trial.

Hong S, Park CY, Han KA, Chung CH, Ku BJ, Jang HC, Ahn CW, Lee MK, Moon MK, Son HS, Lee CB, Cho YW, Park SW.

Diabetes Obes Metab. 2016 May;18(5):528-32. doi: 10.1111/dom.12631.

14.

The Dipeptidyl Peptidase-4 Inhibitor Teneligliptin Attenuates Hepatic Lipogenesis via AMPK Activation in Non-Alcoholic Fatty Liver Disease Model Mice.

Ideta T, Shirakami Y, Miyazaki T, Kochi T, Sakai H, Moriwaki H, Shimizu M.

Int J Mol Sci. 2015 Dec 8;16(12):29207-18. doi: 10.3390/ijms161226156.

15.

Teneligliptin: a review in type 2 diabetes.

Scott LJ.

Clin Drug Investig. 2015 Nov;35(11):765-72. doi: 10.1007/s40261-015-0348-9. Review.

PMID:
26475720
16.

Pharmacokinetic and protein binding profile of peptidomimetic DPP-4 inhibitor - Teneligliptin in rats using liquid chromatography-tandem mass spectrometry.

Shantikumar S, Satheeshkumar N, Srinivas R.

J Chromatogr B Analyt Technol Biomed Life Sci. 2015 Oct 1;1002:194-200. doi: 10.1016/j.jchromb.2015.08.023.

PMID:
26340762
17.

Improved glycemic control with teneligliptin in patients with type 2 diabetes mellitus on hemodialysis: Evaluation by continuous glucose monitoring.

Wada N, Mori K, Nakagawa C, Sawa J, Kumeda Y, Shoji T, Emoto M, Inaba M.

J Diabetes Complications. 2015 Nov-Dec;29(8):1310-3. doi: 10.1016/j.jdiacomp.2015.07.002.

PMID:
26298521
18.

Teneligliptin improves left ventricular diastolic function and endothelial function in patients with diabetes.

Hashikata T, Yamaoka-Tojo M, Kakizaki R, Nemoto T, Fujiyoshi K, Namba S, Kitasato L, Hashimoto T, Kameda R, Maekawa E, Shimohama T, Tojo T, Ako J.

Heart Vessels. 2016 Aug;31(8):1303-10. doi: 10.1007/s00380-015-0724-7. Erratum in: Heart Vessels. 2016 Aug;31(8):1311-2.

PMID:
26266630
19.

Teneligliptin improves metabolic abnormalities in a mouse model of postmenopausal obesity.

Sameshima A, Wada T, Ito T, Kashimura A, Sawakawa K, Yonezawa R, Tsuneki H, Ishii Y, Sasahara M, Saito S, Sasaoka T.

J Endocrinol. 2015 Oct;227(1):25-36. doi: 10.1530/JOE-15-0239.

20.

Teneligliptin, a Dipeptidyl Peptidase-4 Inhibitor, Improves Early-Phase Insulin Secretion in Drug-Naïve Patients with Type 2 Diabetes.

Ito R, Fukui T, Hayashi T, Osamura A, Ohara M, Hara N, Higuchi A, Yamamoto T, Hirano T.

Drugs R D. 2015 Sep;15(3):245-51. doi: 10.1007/s40268-015-0096-6.

Items per page

Supplemental Content

Loading ...
Support Center